Literature DB >> 16918971

Clinical significance of CK5/6 and PTEN protein expression in patients with bilateral breast carcinoma.

J H Piekarski1, W Biernat.   

Abstract

AIMS: To assess the expression of cytokeratin (CK) 5/6 in bilateral breast cancers and to assess the relationship between its expression and other prognostic variables, as well as between CK5/6 expression and patients' survival. METHODS AND
RESULTS: The expression of CK5/6, PTEN protein, oestrogen receptor, progesterone receptor, p53 and c-erbB-2 protein were evaluated by immunohistochemistry in 88 primary breast cancers diagnosed in 44 women. To assess the prognostic value of studied factors, Cox regression analysis was performed. Expression of CK5/6 was found in 23 of 88 primary breast carcinomas (23/88; 26%). The hazard ratio of development of distant metastasis in patients in whom at least one cancer was CK5/6+ was 99.8 (P=0.037) and in patients with at least one carcinoma with reduced PTEN expression it was 10.8 (P=0.044). CK5/6 expression was correlated with absence of oestrogen (P<0.0001) and progesterone receptors (P<0.0001) and very strong expression of p53 (P<0.05). Reduced PTEN expression was correlated with presence of axillary metastases (P<0.01), with very strong expression of c-erbB-2 (P<0.05) and with reduced expression of oestrogen receptor (P<0.05).
CONCLUSIONS: Analysis of expression of CK5/6 and PTEN protein in bilateral breast carcinomas may be of value in clinical practice and warrant further studies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16918971     DOI: 10.1111/j.1365-2559.2006.02482.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  4 in total

1.  Association of sporadic breast cancer with PTEN/MMAC1/TEP1 promoter hypermethylation.

Authors:  Vallian Sadeq; Nassiri Isar; Tavassoli Manoochehr
Journal:  Med Oncol       Date:  2010-03-17       Impact factor: 3.064

2.  Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer.

Authors:  Mevlude Inanc; Metin Ozkan; Halit Karaca; Veli Berk; Oktay Bozkurt; Ayse Ocak Duran; Ersin Ozaslan; Hulya Akgun; Fatos Tekelioglu; Ferhan Elmali
Journal:  Med Oncol       Date:  2013-12-11       Impact factor: 3.064

3.  Clinicopathlogic and immunohistochemical characteristics of triple negative invasive lobular carcinoma.

Authors:  Ja Seung Koo; Woohee Jung
Journal:  Yonsei Med J       Date:  2011-01       Impact factor: 2.759

4.  Prognostic value of protein tyrosine kinase 6 (PTK6) for long-term survival of breast cancer patients.

Authors:  M Aubele; A K Walch; N Ludyga; H Braselmann; M J Atkinson; B Luber; G Auer; S Tapio; T Cooke; J M S Bartlett
Journal:  Br J Cancer       Date:  2008-09-09       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.